Biotech Values

[oc631]

Since few new patients are becoming infected with HCV, the pool of patients to be treated will be much smaller in 10 years than it is today.

The growth number of HCV patients in the undeveloped world will exceed the number that receive treatment over the next 10 years IMO. China, India, and SE Asia will be particularly strong and profitable HCV drug markets if economic growth projections are maintained and intellectual property rights are respected.